A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer.

J Breast Cancer · 2026 · PMC13144639 · PMID 41918183

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Additionally, high TIL levels, a known favorable prognostic factor in TNBC associated with improved survival and a higher likelihood of pCR [ 33 ], also demonstrated a favorable trend for pCR in our cohort.

also in 1,005 other papers

showed a trendno p-value reported

This is crucial because neoadjuvant pembrolizumab plus chemotherapy showed a trend toward greater benefits in the Asian subgroup of the KEYNOTE-522 trial population in terms of EFS and pCR rates [ 12 ].

also in 33,481 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.